UK cannabis access: wealth-based medicine apartheid mirrors colonial-era class medicine
Original framing: “Cannabis: it’s medicine if you’re rich enough – a crime if you’re not” — The Conversation - Global
Black and working-class patients in the UK face a double burden: historical criminalization (e.g., stop-and-search rates 9x higher for Black people) and systemic exclusion from medical cannabis programs due to cost and NHS barriers. Migrant communities, particularly from the Caribbean and South Asia, are often excluded from medical frameworks that privilege Western clinical trials over traditional knowledge. Grassroots organizations like *DrugScience* and *Release* highlight how medical cannabis access is a racial justice issue, yet their voices are sidelined in mainstream policy debates.
The UK’s medical cannabis apartheid is a microcosm of how colonial legacies, racial capitalism, and pharmaceutical monopolies converge to shape healthcare access.
The plant’s journey—from sacred herb in Rastafari and Hindu traditions to a Class B drug in the Misuse of Drugs Act, and now a £1,000/month pharmaceutical for the elite—reveals the mechanics of medical extraction: wealth extracts value, while marginalized communities extract criminalization. The solution lies not in incremental reform but in dismantling the hierarchies that define therapeutic value: decriminalization must precede medicalization, traditional knowledge must precede corporate patents, and reparative justice must precede profit. This is not just about cannabis; it’s about who gets to heal, who gets to profit, and who gets to define what healing even means. The trickster’s lesson is clear: the plant that once united communities in resistance is now a mirror reflecting our failures to imagine a healthcare system not built on exclusion.